87 related articles for article (PubMed ID: 10732868)
1. p53 status in breast carcinomas revealed by FASAY correlates well with p53 protein accumulation determined by immunohistochemistry.
Smardová J; Vagunda V; Jandáková E; Vagundová M; Koukalová H; Kovarík J; Zaloudík J
Neoplasma; 1999; 46(6):384-9. PubMed ID: 10732868
[TBL] [Abstract][Full Text] [Related]
2. Spectrum of p53 mutations in biopsies from breast cancer patients selected for preoperative chemotherapy analysed by the functional yeast assay to predict therapeutic response.
Deissler H; Kafka A; Schuster E; Sauer G; Kreienberg R; Zeillinger R
Oncol Rep; 2004 Jun; 11(6):1281-6. PubMed ID: 15138567
[TBL] [Abstract][Full Text] [Related]
3. Correlations of breast carcinoma biomarkers and p53 tested by FASAY and immunohistochemistry.
Vagunda V; Smardová J; Vagundová M; Jandáková E; Zaloudík J; Koukalová H
Pathol Res Pract; 2003; 199(12):795-801. PubMed ID: 14989491
[TBL] [Abstract][Full Text] [Related]
4. Assessment of the transcriptional activity of p53 improves the prediction of recurrence in superficial transitional cell carcinoma of the bladder.
Dekairelle AF; Tombal B; Cosyns JP; Gala JL
Clin Cancer Res; 2005 Jul; 11(13):4724-32. PubMed ID: 16000567
[TBL] [Abstract][Full Text] [Related]
5. p53 protein accumulation detected by five different antibodies: relationship to prognosis and heat shock protein 70 in breast cancer.
Elledge RM; Clark GM; Fuqua SA; Yu YY; Allred DC
Cancer Res; 1994 Jul; 54(14):3752-7. PubMed ID: 8033095
[TBL] [Abstract][Full Text] [Related]
6. Specificity of seven monoclonal antibodies against p53 evaluated with Western blotting, immunohistochemistry, confocal laser scanning microscopy, and flow cytometry.
Bonsing BA; Corver WE; Gorsira MC; van Vliet M; Oud PS; Cornelisse CJ; Fleuren GJ
Cytometry; 1997 May; 28(1):11-24. PubMed ID: 9136751
[TBL] [Abstract][Full Text] [Related]
7. Identification of a transcriptionally inactive p53 mutant by functional analysis of separated alleles in yeasts (FASAY) in a child osteosarcoma tumor: a case report.
Dekairelle AF; Brichard B; Delhez H; Gala JL
Pediatr Hematol Oncol; 2004 Jun; 21(4):321-8. PubMed ID: 15205094
[TBL] [Abstract][Full Text] [Related]
8. Screen p53 mutations in hepatocellular carcinoma by FASAY: a novel splicing mutation.
Wu XM; Fu JG; Ge WZ; Zhu JY; Wang JY; Zhang W; Qian W; Huo KK
J Zhejiang Univ Sci B; 2007 Feb; 8(2):81-7. PubMed ID: 17266182
[TBL] [Abstract][Full Text] [Related]
9. Clinical evaluation of p53 mutations in urothelial carcinoma by IHC and FASAY.
Watanabe J; Nishiyama H; Okubo K; Takahashi T; Toda Y; Habuchi T; Kakehi Y; Tada M; Ogawa O
Urology; 2004 May; 63(5):989-93. PubMed ID: 15135005
[TBL] [Abstract][Full Text] [Related]
10. [Analyses of p53 mutations in breast cancers with a combined use of yeast functional assay and immunohistochemical staining].
Takahashi M
Hokkaido Igaku Zasshi; 1998 May; 73(3):275-86. PubMed ID: 9719952
[TBL] [Abstract][Full Text] [Related]
11. A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients.
Alsner J; Jensen V; Kyndi M; Offersen BV; Vu P; Børresen-Dale AL; Overgaard J
Acta Oncol; 2008; 47(4):600-7. PubMed ID: 18465328
[TBL] [Abstract][Full Text] [Related]
12. Analysis of p53 status in human cell lines using a functional assay in yeast: detection of new non-sense p53 mutation in codon 124.
Smardová J; Pavlová S; Svitáková M; Grochová D; Ravcuková B
Oncol Rep; 2005 Oct; 14(4):901-7. PubMed ID: 16142349
[TBL] [Abstract][Full Text] [Related]
13. Improving the detection of p53 mutations in breast cancer by use of the FASAY, a functional assay.
Duddy PM; Hanby AM; Barnes DM; Camplejohn RS
J Mol Diagn; 2000 Aug; 2(3):139-44. PubMed ID: 11229518
[TBL] [Abstract][Full Text] [Related]
14. [Comparison of nuclear accumulation of p53 protein with mutations in the p53 gene on the tissues of human breast cancer].
Fan P; Wu Z; Cha X; Wang X; Wang S
Zhonghua Wai Ke Za Zhi; 1998 Nov; 36(11):655-7. PubMed ID: 11825490
[TBL] [Abstract][Full Text] [Related]
15. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.
Holstege H; Joosse SA; van Oostrom CT; Nederlof PM; de Vries A; Jonkers J
Cancer Res; 2009 Apr; 69(8):3625-33. PubMed ID: 19336573
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical detection of p53 protein expression in breast cancer in young Kuwaiti women.
Temmim L; Baker H; Sinowatz F
Anticancer Res; 2001; 21(1B):743-8. PubMed ID: 11299837
[TBL] [Abstract][Full Text] [Related]
17. Analysis of tumor suppressor p53 status in head and neck squamous cell carcinoma.
Smardova J; Ksicova K; Binkova H; Krpensky A; Pavlova S; Rottenberg J; Koukalova H
Oncol Rep; 2004 Apr; 11(4):923-9. PubMed ID: 15010896
[TBL] [Abstract][Full Text] [Related]
18. Significance of the expression of hormone receptors and of p53 protein in breast carcinomas.
Roşianu A; Tudose N; Potencz E
Rom J Morphol Embryol; 1996; 42(1-2):63-71. PubMed ID: 9038388
[TBL] [Abstract][Full Text] [Related]
19. High frequency of temperature-sensitive mutations of p53 tumor suppressor in acute myeloid leukemia revealed by functional assay in yeast.
Pavlova S; Mayer J; Koukalova H; Smardova J
Int J Oncol; 2003 Jul; 23(1):121-31. PubMed ID: 12792784
[TBL] [Abstract][Full Text] [Related]
20. Correlation between p53 expression and other prognostic factors in breast cancer.
Roşianu A; Tudose N
Rom J Morphol Embryol; 1998; 44(1-4):133-40. PubMed ID: 15678854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
